New hope for HIV patients with blood cancer: safer bone marrow transplants on the horizon?

NCT ID NCT05470491

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 17 times

Summary

This study tests whether a combination of three drugs (cyclophosphamide, bortezomib, and maraviroc) can safely prevent graft-versus-host disease after a half-matched bone marrow transplant in people living with HIV who also have a blood cancer. The trial involves 265 participants and has two phases: first to check safety, then to see if the drug combo works better than standard care. Participants will be hospitalized for about 6 weeks and followed for up to 5 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cyclophosphamide, bortezomib, and maraviroc
What this could lead to: If successful, this could offer a safer way to perform bone marrow transplants in people with HIV, potentially improving cancer control and survival.
What could go wrong: This is an early-phase trial (Phase I/II) with a small number of participants, so the new drug combo may not prove safer or more effective than standard care. There are also risks of serious side effects like graft-versus-host disease and infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNANCIES HIV

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.